| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yehudit Hasin, Nili Avidan, Dani Bercovich, Amos Korczyn, Israel Silman, Jacques S Beckmann, Joel L Sussma. A paradigm for single nucleotide polymorphism analysis: the case of the acetylcholinesterase gene. Human mutation. vol 24. issue 5. 2005-07-29. PMID:15459952. |
furthermore, the newly identified snps open the door to a study of the possible association of ache with deleterious phenotypes-such as adverse drug responses to ache inhibitors employed in treatment of alzheimer patients and hypersensitivity to pesticides. |
2005-07-29 |
2023-08-12 |
human |
| Héric Valette, Michel Bottlaender, Frédéric Dollé, Christine Coulon, Michèle Ottaviani, André Syrot. Acute effects of physostigmine and galantamine on the binding of [18F]fluoro-A-85380: a PET study in monkeys. Synapse (New York, N.Y.). vol 56. issue 4. 2005-07-29. PMID:15803498. |
physostigmine, a potent ache inhibitor, and galantamine, an allosteric modulator of nachrs, are widely used for the treatment of alzheimer's disease. |
2005-07-29 |
2023-08-12 |
monkey |
| Nicolaas I Bohnen, Daniel I Kaufer, Rick Hendrickson, Larry S Ivanco, Brian Lopresti, James G Davis, Gregory Constantine, Chester A Mathis, Robert Y Moore, Steven T DeKosk. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neuroscience letters. vol 380. issue 1-2. 2005-07-28. PMID:15854764. |
we recently reported findings of modest loss of cortical acetylcholinesterase (ache) activity in patients with overall mild alzheimer's disease (ad) using n-[11c]methyl-pi-peridin-4-yl propionate ([11c]pmp) ache positron emission tomography (pet). |
2005-07-28 |
2023-08-12 |
human |
| Nibaldo C Inestrosa, Soledad Urra, Marcela Colombre. Acetylcholinesterase (AChE)--amyloid-beta-peptide complexes in Alzheimer's disease. the Wnt signaling pathway. Current Alzheimer research. vol 1. issue 4. 2005-07-21. PMID:15975054. |
acetylcholinesterase (ache)--amyloid-beta-peptide complexes in alzheimer's disease. |
2005-07-21 |
2023-08-12 |
rat |
| Rommy von Bernhardi, Rodrigo Alarcón, Diego Mezzano, Patricio Fuentes, Nibaldo C Inestros. Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia. Dementia and geriatric cognitive disorders. vol 19. issue 4. 2005-07-15. PMID:15677868. |
blood acetylcholinesterase (ache) and butyrylcholinesterase (buche) activities have been studied as markers for alzheimer's disease (ad), but their usefulness as a disease marker is controversial. |
2005-07-15 |
2023-08-12 |
human |
| Lynnette J Cook, Luk W Ho, Lin Wang, Edith Terrenoire, Carol Brayne, John Grimley Evans, John Xuereb, Nigel J Cairns, Dragana Turic, Paul Hollingworth, Pamela J Moore, Luke Jehu, Nicola Archer, Sarah Walter, Catherine Foy, Amanda Edmondson, John Powell, Simon Lovestone, Julie Williams, David C Rubinsztei. Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 132B. issue 1. 2005-05-12. PMID:15690550. |
consistent deficits in the cholinergic system are evident in the brains of alzheimer's disease (ad) patients, including reductions in the activities of acetylcholine, acetylcholinesterase (ache), and choline acetyltransferase (chat), increased butyrylcholinesterase (bche) activity, and a selective loss of nicotinic acetylcholine receptors (nachrs). |
2005-05-12 |
2023-08-12 |
Not clear |
| Emmanuel Stip, Sylvie Chouinard, Luc Jean Boula. On the trail of a cognitive enhancer for the treatment of schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 29. issue 2. 2005-05-09. PMID:15694228. |
a few studies have suggested that cholinomimetics or ache inhibitors can improve memory functions not only in alzheimer's disease but also in other pathologies. |
2005-05-09 |
2023-08-12 |
Not clear |
| Tatsuya Kikuchi, Ming-Rong Zhang, Nobuo Ikota, Kiyoshi Fukushi, Toshimitsu Okamura, Kazutoshi Suzuki, Yasushi Arano, Toshiaki Iri. N-[18F] fluoroethylpiperidin-4ylmethyl acetate, a novel lipophilic acetylcholine analogue for PET measurement of brain acetylcholinesterase activity. Journal of medicinal chemistry. vol 48. issue 7. 2005-05-05. PMID:15801847. |
the reduction of acetylcholinesterase (ache) activity in the brain has been measured in dementia disorders such as alzheimer's disease and dementia with lewy bodies using (11)c-labeled acetylcholine analogues, n-[(11)c]methylpiperidin-4-yl acetate and propionate, and positron emission tomography (pet). |
2005-05-05 |
2023-08-12 |
human |
| Ido Layish, Amir Krivoy, Eran Rotman, Arseny Finkelstein, Zeev Tashma, Yoav Yehezkell. Pharmacologic prophylaxis against nerve agent poisoning. The Israel Medical Association journal : IMAJ. vol 7. issue 3. 2005-04-26. PMID:15792266. |
these include combinations of carbamates (reversible ache inhibitors) and central anticholinergics or nmda receptor antagonists, benzodiazepines or partial agonists for benzodiazepine receptor, and other central ache inhibitors approved for alzheimer's disease. |
2005-04-26 |
2023-08-12 |
Not clear |
| Michihisa Tohda, Prawpan Suwanakitch, Rattima Jeenapongsa, Hisae Hayashi, Hiroshi Watanabe, Kinzo Matsumot. Expression changes of the mRNA of Alzheimer's disease related factors in the permanent ischemic rat brain. Biological & pharmaceutical bulletin. vol 27. issue 12. 2005-04-15. PMID:15577224. |
the expression changes of amyloid precursor protein (app), secretase, alpha7 nicotinic acetylcholine receptor (alpha7nicr) and acetylcholine esterase (ache), which are involved in alzheimer's disease, were examined by quantitative rt/pcr in this model rat brain. |
2005-04-15 |
2023-08-12 |
rat |
| Hugo Geerts, Pierre-Olivier Guillaumat, Christopher Grantham, Wilhelmina Bode, Katelijne Anciaux, Sohel Sacha. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain research. vol 1033. issue 2. 2005-04-13. PMID:15694923. |
galantamine is a rather weak acetylcholinesterase (ache) inhibitor, currently approved for the symptomatic treatment of alzheimer's disease, with possible additional allosteric potentiating effects at the nicotinic ach receptor (nachr). |
2005-04-13 |
2023-08-12 |
mouse |
| Nibaldo C Inestrosa, Juan Paulo Sagal, Marcela Colombre. Acetylcholinesterase interaction with Alzheimer amyloid beta. Sub-cellular biochemistry. vol 38. 2005-04-12. PMID:15709485. |
the fact that ache is able to accelerate amyloid formation and that such effect is sensitive to drugs that block pas of the enzyme, suggests that specific and new ache inhibitors may well provide an attractive possibility for treating alzheimer's disease. |
2005-04-12 |
2023-08-12 |
rat |
| N I Bohnen, D I Kaufer, R Hendrickson, L S Ivanco, B J Lopresti, R A Koeppe, C C Meltzer, G Constantine, J G Davis, C A Mathis, S T Dekosky, R Y Moor. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry. vol 76. issue 3. 2005-03-15. PMID:15716518. |
to determine in vivo cortical acetylcholinesterase (ache) activity and cognitive effects in subjects with mild alzheimer's disease (ad, n = 14) prior to and after 12 weeks of donepezil therapy. |
2005-03-15 |
2023-08-12 |
human |
| Z-X She. Brain cholinesterases: I. The clinico-histopathological and biochemical basis of Alzheimer's disease. Medical hypotheses. vol 63. issue 2. 2005-02-24. PMID:15236793. |
in alzheimer's disease (ad), the histopathological characteristics are initially and primarily associated with the degeneration of the acetylcholinesterase (ache) system in various brain regions. |
2005-02-24 |
2023-08-12 |
Not clear |
| Maria Laura Bolognesi, Vincenza Andrisano, Manuela Bartolini, Rita Banzi, Carlo Melchiorr. Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation. Journal of medicinal chemistry. vol 48. issue 1. 2005-02-17. PMID:15633997. |
the peculiar biological profile of 4 can be relevant in studying the molecular basis underlying the nonclassical action of ache and in addressing the question whether ache inhibitors can affect the neurotoxic cascade leading to alzheimer's disease. |
2005-02-17 |
2023-08-12 |
Not clear |
| Franco Giubilei, Caterina Calderaro, Giovanni Antonini, Micaela Sepe-Monti, Paolo Tisei, Ercole Brunetti, Francesca Marchione, Brunella Caronti, Francesco E Pontier. Increased lymphocyte dopamine beta-hydroxylase immunoreactivity in Alzheimer's disease: compensatory response to cholinergic deficit? Dementia and geriatric cognitive disorders. vol 18. issue 3-4. 2005-02-16. PMID:15305112. |
here we show a slight decrease in acetylcholinesterase (ache) and a significant increase in dopamine beta-hydroxylase (dbh) immunoreactivity in the pbl of patients with probable alzheimer's disease (ad). |
2005-02-16 |
2023-08-12 |
Not clear |
| Gregory E Garcia, Rickey P Hicks, David Skanchy, Deborah R Moorad-Doctor, Bhupendra P Doctor, Haresh S Ve. Identification and characterization of the major huperzine a metabolite in rat blood. Journal of analytical toxicology. vol 28. issue 5. 2005-02-14. PMID:15239859. |
huperzine a (hup a) is under investigation as a treatment of alzheimer's disease because of its properties of reversible and specific ache inhibition. |
2005-02-14 |
2023-08-12 |
rat |
| Marco Racchi, Michela Mazzucchelli, Emanuela Porrello, Cristina Lanni, Stefano Govon. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacological research. vol 50. issue 4. 2005-02-04. PMID:15304241. |
the therapeutic approach for improving the cognitive function in patients with alzheimer's disease (ad) is mainly based on the potentiation of central cholinergic activity and is achieved clinically by the use of acetylcholinesterase (ache) inhibitors such as tacrine, donepezil, rivastigmine, galantamine and other drugs currently in clinical trials. |
2005-02-04 |
2023-08-12 |
Not clear |
| Silvia Di Angelantonio, Giorgio Bernardi, Nicola B Mercur. Methamidophos transiently inhibits neuronal nicotinic receptors of rat substantia nigra dopaminergic neurons via open channel block. Neuroscience letters. vol 369. issue 3. 2005-01-13. PMID:15464266. |
the use of acetylcholinesterase (ache) inhibitors is the primary therapeutic strategy in the treatment of alzheimer's disease. |
2005-01-13 |
2023-08-12 |
rat |
| Maria Laura Bolognesi, Manuela Bartolini, Andrea Cavalli, Vincenza Andrisano, Michela Rosini, Anna Minarini, Carlo Melchiorr. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. Journal of medicinal chemistry. vol 47. issue 24. 2005-01-03. PMID:15537349. |
rivastigmine (1), an acetylcholinesterase (ache) inhibitor approved in 2000 for the treatment of alzheimer disease, bears a carbamate moiety in its structure, which is able to react covalently with the active site of the enzyme. |
2005-01-03 |
2023-08-12 |
human |